PHARMARESEARCH BIO Co. Ltd.
KKRX:21795028,800.00
KRW
-300.00
(-1.03%)
ISIN
KR7217950005
Return %
Stock
S&P 500
1Y
-10.28
14.20
3Y
43.28
81.12
5Y
-19.67
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 103
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Gangneung-si South Korea
- IPO Date
- Oct 15, 2015
- Website
- pr-bio.co.kr
- Similar Companies
- Business
- PharmaResearch BIO Co. Ltd. is a South Korea-based biopharmaceutical company specializing in the research, development, and manufacturing of biological therapeutics and aesthetic injectable products, with a primary focus on botulinum toxin formulations. Founded in 2009 and headquartered in Gangneung-si, Gangwon-do, South Korea, the company operates as a biopharmaceutical manufacturing subsidiary of PharmaResearch Co., Ltd. and is listed on the Korea New Exchange under ticker 217950. The company's core operations and offerings encompass: botulinum toxin type A injectables, featuring its proprietary ReNTox (Re N Tox) brand available in 100-unit and 200-unit lyophilized powder presentations indicated for aesthetic applications such as the temporary improvement of moderate-to-severe glabellar lines and dynamic facial wrinkles, as well as therapeutic applications including upper limb spasticity, blepharospasm, and dynamic equinus foot deformity; next-generation biological pipeline candidates, notably proprietary long-acting neurotoxin formulations combining polynucleotides (PN) with botulinum toxin type A designed to prolong muscle relaxation efficacy, alongside pipeline programs such as PRB-002, PRB-004, and PRB-005; and biological contract manufacturing, fill-finish, and cold-chain export distribution services catering to healthcare providers, aesthetic clinics, and medical distributors across Asia, Latin America, and other international markets. In recent operational developments, PharmaResearch BIO secured domestic product approval from the South Korean Ministry of Food and Drug Safety (MFDS) for ReNTox 100-unit and commenced commercial domestic market distribution, expanding beyond its historical export-only footprint. The company also advanced its international regulatory expansion by obtaining market authorization from the Thailand Food and Drug Administration (TFDA). To accommodate accelerated global demand, the company completed and operationalized its second Good Manufacturing Practice (GMP) production facility at its Gangneung complex, increasing total manufacturing capacity to approximately six million vials per year while strengthening commercial synergies with its parent company under a total aesthetic medical solutions strategy.